Why the study?
The effect of sacubitril-valsartan in heart failure patients with mid-range ejection fraction remains unclear.
Does sacubitril-valsartan improve left ventricular function, quality of life, and reduce readmission rates in patients with heart failure with mid-range ejection fractions compared to ACEI or ARB?
Population
1,937 HFmrEF patients across 16 studies
Comparison
Sacubitril-valsartan (ARNI) vs ACEI or ARB
Design
Systematic review and meta-analysis
Authors
Loading...
ARNI improves LV function and QoL in HFmrEF; extends ARNI benefits beyond HFrEF with prior limited data.
Does sacubitril-valsartan improve left ventricular function, quality of life, and reduce readmission rates in patients with heart failure with mid-range ejection fractions compared to ACEI or ARB?
Sacubitril-valsartan may improve left ventricular function, quality of life, and reduce readmission rates in patients with HFmrEF compared to ACEI or ARB.
Qin et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: